Suppr超能文献

眼内肾上腺素注射对超声乳化术后无并发症的黄斑厚度的影响。

Effect of intracameral epinephrine use on macular thickness after uneventful phacoemulsification.

机构信息

Beyoğlu Eye Training and Research Hospital, Istanbul, Turkey.

出版信息

J Cataract Refract Surg. 2010 Aug;36(8):1380-4. doi: 10.1016/j.jcrs.2010.02.020.

Abstract

PURPOSE

To evaluate changes in central macular thickness using optical coherence tomography after uneventful cataract surgery combined with intracameral epinephrine use.

SETTING

Beyoğlu Eye Training and Research Hospital, Istanbul, Turkey.

METHODS

This prospective case series comprised eyes of consecutive patients who had uneventful phacoemulsification and in-the-bag intraocular lens (IOL) implantation between August 2005 and January 2006. The eyes were randomly assigned to 1 of 2 groups. In 1 group, 0.2 mL epinephrine (1:5000 solution) was injected just after the clear corneal incision was created. The other group (control) did not receive epinephrine. Optical coherence tomography was performed in all eyes preoperatively as well as postoperatively at 1 day, 1 week, and 1, 3, and 6 months.

RESULTS

The epinephrine group comprised 73 eyes (73 patients) and the control group, 76 eyes (86 patients). In both groups, the increase in retinal thickness from preoperatively to 1, 3, and 6 months postoperatively was statistically significant (P<.05); the difference was not statistically significant at 1 day or 1 week in either group (P>.05). There were no statistically significant differences between the 2 groups in mean retinal thickness throughout the follow-up (P>.05). Clinically significant macular edema occurred in 3 eyes in the epinephrine group and 3 eyes in the control group.

CONCLUSION

Although epinephrine is a well-known risk factor for central macular edema, intracameral injection of 0.2 mL epinephrine (1:5000) did not increase the risk for central macular edema in eyes with no risk factors that had uneventful phacoemulsification with IOL implantation.

FINANCIAL DISCLOSURE

No author has a financial or proprietary interest in any material or method mentioned.

摘要

目的

评估白内障手术后无并发症且眼内注射肾上腺素时中央黄斑厚度的变化。

地点

土耳其伊斯坦布尔贝尤鲁眼训练与研究医院。

方法

本前瞻性病例系列研究包括 2005 年 8 月至 2006 年 1 月期间接受无并发症超声乳化白内障吸除术和囊袋内人工晶状体(IOL)植入术的连续患者的眼睛。这些眼睛被随机分配到 2 组中的 1 组。在 1 组中,在创建透明角膜切口后立即注射 0.2 毫升肾上腺素(1:5000 溶液)。另一组(对照组)未接受肾上腺素。所有眼睛在术前以及术后 1 天、1 周、1、3 和 6 个月进行光学相干断层扫描。

结果

肾上腺素组包括 73 只眼(73 例),对照组包括 76 只眼(86 例)。在两组中,从术前到术后 1、3 和 6 个月,视网膜厚度的增加均具有统计学意义(P<.05);在两组中,术后 1 天或 1 周时差异均无统计学意义(P>.05)。在整个随访过程中,两组之间的平均视网膜厚度无统计学差异(P>.05)。肾上腺素组中有 3 只眼和对照组中有 3 只眼发生了临床显著的黄斑水肿。

结论

尽管肾上腺素是中央黄斑水肿的一个众所周知的危险因素,但在没有危险因素的情况下,进行无并发症超声乳化白内障吸除术和 IOL 植入术后,眼内注射 0.2 毫升肾上腺素(1:5000)不会增加中央黄斑水肿的风险。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验